Taysha Gene Therapies, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $5.5M | $0 | $2.0M | $2.3M | $2.0M | $1.8M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $38.6M | $33.8M | $25.0M | $25.7M | $20.1M | $15.6M | $15.3M | $14.9M |
| SG&A Expense | $12.1M | $9.7M | $8.8M | $8.3M | $8.6M | $8.2M | $6.6M | $7.9M |
| Operating Income | $-47.3M | $-43.5M | $-28.3M | $-34.0M | $-26.8M | $-21.4M | $-19.9M | $-25.9M |
| Operating Margin | — | — | -516.0% | — | -1,347.1% | -930.5% | -985.8% | -1,448.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | — | — | — | $0 | — | — |
| Net Income | $-46.6M | $-42.4M | $-27.9M | $-32.7M | $-26.9M | $-21.5M | $-18.8M | $-25.5M |
| Net Margin | — | — | -507.8% | — | -1,353.6% | -935.2% | -929.0% | -1,427.5% |
| EPS (Basic) | $-0.13 | $-0.12 | $-0.08 | $-0.05 | $-0.09 | $-0.08 | $-0.07 | $-0.05 |
| EPS (Diluted) | $-0.13 | $-0.12 | $-0.08 | $-0.05 | $-0.09 | $-0.08 | $-0.07 | $-0.05 |
| Shares Outstanding (Basic) | 369.0M | 366.6M | 319.7M | 706.6M | 298.0M | 269.3M | 250.1M | 535.6M |
| Shares Outstanding (Diluted) | 369.0M | 366.6M | 319.7M | 706.6M | 298.0M | 269.3M | 250.1M | 535.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |